Euronews is no longer accessible on Internet Explorer. This browser is not updated by Microsoft and does not support the last technical evolutions. We encourage you to use another browser, such as Edge, Safari, Google Chrome or Mozilla Firefox.
BREAKING NEWS

AstraZeneca's Imfinzi misses main goal of advanced lung cancer study

AstraZeneca's Imfinzi misses main goal of advanced lung cancer study
FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid -
Copyright
BRENDAN MCDERMID(Reuters)
Euronews logo
Text size Aa Aa

(Reuters) – London-listed drugmaker AstraZeneca Plc <AZN.L> said on Wednesday its immunotherapy treatment Imfinzi did not meet the main goal of a late-stage study for advanced non-small cell lung cancer.

The treatment was not successful in extending the lives of patients whose cancer had spread to other parts of the body. The primary group in the study also had high levels of mutations in their DNA, the company said.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on euronews.com for a limited time.